Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1684.

https://doi.org/10.1182/blood.V128.22.1684.1684

Published: 2016

Journal Articles

Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

Blood (2015) 126 (23): 306.

https://doi.org/10.1182/blood.V126.23.306.306

Published: 2015

Journal Articles

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Deepak Singhal, MD FRCPA, Sophia Hague, BAppSc (MDc), David Roxby, MAppSc AFRCPA FFSc[RCPA], L Amilia Wee, BSc(Hons), Oi-Lin Lee, MBBS, FRCPA, Romi Sinha, MBBS, MIBMS, FACHI, Rakchha Chhetri, MBBS, James X Gray, MBBS, FRACP, FRCPA, MD PhD, Pratyush Giri, MBBS, FRACP, FRCPA, Kathryn Robinson, MBBS, FRACP, FRCPA, Shriram Nath, MBBS, DM, FRCPA, Nicholas Wickham, FRCPA,FRACP,FRCPath, Chi-hung Hui, MBBS, MRCP, FRCPath, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, L Bik To, MBBS, FRACP, FRCPA, PhD, Devendra K Hiwase, MBBS, FRACP, FRCPA, MD PhD

Blood (2015) 126 (23): 3562.

https://doi.org/10.1182/blood.V126.23.3562.3562

Published: 2015

Journal Articles

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Rami S. Komrokji, John F. Seymour, Andrew W. Roberts, Martha Wadleigh, L. Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S. Campbell, Ruben A. Mesa

Blood (2015) 125 (17): 2649–2655.

https://doi.org/10.1182/blood-2013-02-484832

Published: 2015

Includes: Supplemental data

Journal Articles

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Monika M Kutyna, Rakchha Chhetri, Stuart Howell, Peter B Harrison, Shriram V Nath, Lakshmi S Nath, Nicholas Wickham, Ferenc Szabo, Chi-Hung Hui, David Ross, James Gray, Junia V Melo, MD, PhD, Peter Bardy, L. Bik To

Blood (2013) 122 (21): 1518.

https://doi.org/10.1182/blood.V122.21.1518.1518

Published: 2013

Journal Articles

A Regulatory Promoter Polymorphism and Hypermethylation of Intron 1 Are Associated with Reduced Expression of KLF5 and Inferior Survival in AML

Anna L Brown, PhD, Sonya M Diakiw, PhD, Michelle Perugini, PhD, Nik Cummings, BSc, Andrew H Wei, MBBS, PhD, L. Bik To, MD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD

Blood (2012) 120 (21): 3508.

https://doi.org/10.1182/blood.V120.21.3508.3508

Published: 2012

Journal Articles

Expression of Erythroid Transcription Factors Are Decreased in a RPS19 Knockdown Cell Line Model of Diamond Blackfan Anaemia

Sarah C E Bray, PhD, Amilia Wee, BSc (hons), Michelle Perugini, PhD, L. Bik To, MD, Richard J D'Andrea, PhD

Blood (2012) 120 (21): 3473.

https://doi.org/10.1182/blood.V120.21.3473.3473

Published: 2012

Journal Articles

Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.

Richard J D'Andrea, PhD, Michelle Perugini, PhD, Sonya M Diakiw, PhD, Chung H Kok, PhD, Diana Salerno, Nik Cummings, BSc, Anna L Brown, PhD, Silke Danner, Peter G Bardy, MBBS, FRACP, FRCPA, Andrew H Wei, MBBS, PhD, L. Bik To, MD, Ian D Lewis, MBBS, PhD

Blood (2012) 120 (21): 2396.

https://doi.org/10.1182/blood.V120.21.2396.2396

Published: 2012

Journal Articles

Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,

Richard J D'Andrea, PhD, Michelle Perugini, PhD, Chung H Kok, PhD, Diana Salerno, Silke Danner, Peter G Bardy, MBBS, FRACP, FRCPA, Andrew H Wei, MBBS, PhD, L. Bik To, MD, Ian D Lewis, MBBS, PhD

Blood (2011) 118 (21): 3540.

https://doi.org/10.1182/blood.V118.21.3540.3540

Published: 2011

Journal Articles

How I treat patients who mobilize hematopoietic stem cells poorly

L. Bik To, Jean-Pierre Levesque, Kirsten E. Herbert

Blood (2011) 118 (17): 4530–4540.

https://doi.org/10.1182/blood-2011-06-318220

Published: 2011

Journal Articles

GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2010) 116 (21): LBA-3.

https://doi.org/10.1182/blood.V116.21.LBA-3.LBA-3

Published: 2010

Journal Articles

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML

Blood (2009) 114 (23): 4859–4870.

https://doi.org/10.1182/blood-2009-02-204818

Published: 2009

Includes: Supplemental data

Journal Articles

Expression Profiling of a Hemopoietic Cell Survival Transcriptome Identifies a Functional Prognostic Gene Signature in Normal Karyotype AML.

Mark Guthridge, Daniel Thomas, MD, Emma F Barry, Kok H Chung, Barbara J McClure, L. Bik To, MD, Greg Goodall, Terry P Speed, Motomi Osato, David Haylock, Susie Nilsson, MD, Richard D'Andrea, PhD, Angel Lopez, Jason A Powell, PhD

Blood (2009) 114 (22): 1618.

https://doi.org/10.1182/blood.V114.22.1618.1618

Published: 2009

Journal Articles

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Devendra K Hiwase, MD, Deborah L White, PhD, Jason A Powell, PhD, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, PhD, L. Bik To, MD, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 3250.

https://doi.org/10.1182/blood.V114.22.3250.3250

Published: 2009

Journal Articles

Long-term imatinib therapy promotes bone formation in CML patients

Stephen Fitter, Andrea L. Dewar, Panagiota Kostakis, L. Bik To, Timothy P. Hughes, Marion M. Roberts, Kevin Lynch, Barrie Vernon-Roberts, Andrew C. W. Zannettino

Blood (2008) 111 (5): 2538–2547.

https://doi.org/10.1182/blood-2007-07-104281

Published: 2008

Includes: Supplemental data

Journal Articles

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Devendra K. Hiwase, MD, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, MD, Junia V. Melo, MD, Timothy P. Hughes, MD

Blood (2007) 110 (11): 1937.

https://doi.org/10.1182/blood.V110.11.1937.1937

Published: 2007

Journal Articles

Cellular origin and lineage specificity of the JAK2 V617F allele in polycythemia vera

Carolyn M. Butcher, Jonathon F. Hutton, Uwe Hahn, L. Bik To, Peter Bardy, Ian Lewis, Richard J. D'Andrea

Blood (2007) 109 (1): 386–387.

https://doi.org/10.1182/blood-2006-07-036426

Published: 2007

Journal Articles

Imatinib as a potential antiresorptive therapy for bone disease

Andrea L. Dewar, Amanda N. Farrugia, Mark R. Condina, L. Bik To, Timothy P. Hughes, Barrie Vernon-Roberts, Andrew C. W. Zannettino

Blood (2006) 107 (11): 4334–4337.

https://doi.org/10.1182/blood-2005-09-3568

Published: 2006

Journal Articles

In Imatinib Treated CML Patients with Low Baseline IC50, Early Molecular Response Is Highly Predictive of Longer Term Molecular Outcome. In Patients with High IC50, Other Prognostic Indicators Are Needed.

Deborah L. White, Susan Branford, Verity A. Saunders, Kevin Lynch, Andrew Grigg, L. Bik To, Timothy P. Hughes

Blood (2005) 106 (11): 3283.

https://doi.org/10.1182/blood.V106.11.3283.3283

Published: 2005

Journal Articles

The In-Vivo Level of Imatinib Induced Kinase Inhibition Achieved in De-Novo CML Patients during the First 28 Days of Therapy Is a Powerful Predictor of Molecular Outcome.

Deborah L. White, Verity A. Saunders, Susan Branford, Kevin Lynch, L. Bik To, Timothy P. Hughes

Blood (2005) 106 (11): 436.

https://doi.org/10.1182/blood.V106.11.436.436

Published: 2005

NARROW

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

A Regulatory Promoter Polymorphism and Hypermethylation of Intron 1 Are Associated with Reduced Expression of KLF5 and Inferior Survival in AML

Expression of Erythroid Transcription Factors Are Decreased in a RPS19 Knockdown Cell Line Model of Diamond Blackfan Anaemia

Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.

Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,

How I treat patients who mobilize hematopoietic stem cells poorly

GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML

Expression Profiling of a Hemopoietic Cell Survival Transcriptome Identifies a Functional Prognostic Gene Signature in Normal Karyotype AML.

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Long-term imatinib therapy promotes bone formation in CML patients

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Cellular origin and lineage specificity of the JAK2 V617F allele in polycythemia vera

Imatinib as a potential antiresorptive therapy for bone disease

In Imatinib Treated CML Patients with Low Baseline IC50, Early Molecular Response Is Highly Predictive of Longer Term Molecular Outcome. In Patients with High IC50, Other Prognostic Indicators Are Needed.

The In-Vivo Level of Imatinib Induced Kinase Inhibition Achieved in De-Novo CML Patients during the First 28 Days of Therapy Is a Powerful Predictor of Molecular Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only